N Engl J Med 384(11):9891002 Horn DB, Kahan S, Batterham RL et al Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
The FDA prescribing information warns about the risk of acute kidney injury in this setting, and patients may require intravenous fluids or temporary medication discontinuation
[10] [11] Additional cautions include: risk of hypoglycaemia when combined with insulin or sulfonylureas
For this retatrutide evidence page, the most relevant search terms are does, retatrutide, show, drug, test
Morling added: Some of the beauty parlours are selling them in this setting not realising that they are selling medicine that could end up giving them a custodial sentence In both customer and seller there is a lack of awareness. The MHRA said that people were seeing products marketed on social media and also finding out about them through word of mouth and visiting local beauty salons
MiguelLSSoaresMOlivieriASampaioFLamotteMShuklaSet al